Tag: competition

Chicago, Illinois, June 16, 2025 (GLOBE NEWSWIRE) -- Mag Mile Capital, Inc. (OTCQB: MMCP) ("Mag Mile", or the "Company") is pleased to announce the successful arrangement of $10.25 million in joint venture equity on behalf of the development team executing an innovative Class A office-to-multifamily conversion project at 111 W. Illinois in the River North neighborhood of Chicago, IL.

MIAMI BEACH, Fla., June 16, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (“AirSculpt”) (NASDAQ: AIRS), a national provider of premium body contouring procedures, today announced the voluntary prepayment of $10.0 million of its outstanding term loan debt using cash on hand, following the successful completion of its offering of 3,634,000 shares of common stock, which generated net proceeds, after estimated expenses, of approximately $13.8 million. The Company noted that with this financing and assuming no significant changes in the current macroeconomic environment, it does not anticipate the need for additional material capital raises this year.

Simplified capital structure bolsters ability to rapidly meet customer demand, reduce interest expense, and increase liquidity

Reference is made to the press release dated 3 June 2025, which stated that certain conditions under the purchase agreement had been fulfilled regarding the acquisition by Orkan IS ehf. (“Orkan”) of all shares held by Kaupfélag Suðurnesja (“KSK”) in Samkaup, with a nominal value of ISK 221,386,719, corresponding to 51.3% of the share capital in Samkaup.

Announcement regarding the governance
of Renault Group

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA¹